These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34897154)

  • 41. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
    Chiu WN; Hung CH; Lu SN; Chen MY; Tung SY; Wei KL; Lu CK; Chen CH; Hu TH; Hu JH; Chen WM; Chang TS
    J Viral Hepat; 2020 Sep; 27(9):866-872. PubMed ID: 32343472
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection.
    Zhou HJ; Wu G; Li JM; Naidoo N; Xie YX; Feng BL; Wang P; Luo JW
    Ann Palliat Med; 2021 Oct; 10(10):10313-10326. PubMed ID: 34670381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).
    Cornberg M; Stoehr A; Naumann U; Teuber G; Klinker H; Lutz T; Möller H; Hidde D; Lohmann K; Simon KG
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.
    de Salazar A; Dietz J; di Maio VC; Vermehren J; Paolucci S; Müllhaupt B; Coppola N; Cabezas J; Stauber RE; Puoti M; Arenas Ruiz Tapiador JI; Graf C; Aragri M; Jimenez M; Callegaro A; Pascasio Acevedo JM; Macias Rodriguez MA; Rosales Zabal JM; Micheli V; Garcia Del Toro M; Téllez F; García F; Sarrazin C; Ceccherini-Silberstein F;
    J Antimicrob Chemother; 2020 Nov; 75(11):3349-3358. PubMed ID: 32772078
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.
    Madsen LW; Christensen PB; Fahnøe U; Pedersen MS; Bukh J; Øvrehus A
    Liver Int; 2021 Nov; 41(11):2601-2610. PubMed ID: 34154034
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.
    Suleiman AA; Lin CW; Liu W; Eckert D; Mensing S; Burroughs M; Kato K; Chayama K; Kumada H; Oberoi RK
    J Clin Pharmacol; 2020 Mar; 60(3):331-339. PubMed ID: 31515816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
    Meszaros M; Truchi R; Ouzan D; Tran A; Bourlière M; Pageaux GP
    Hepatology; 2021 Oct; 74(4):2304-2306. PubMed ID: 34008214
    [No Abstract]   [Full Text] [Related]  

  • 48. Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution.
    Park YJ; Woo HY; Heo J; Park SG; Hong YM; Yoon KT; Kim DU; Kim GH; Kim HH; Song GA; Cho M
    Gut Liver; 2021 May; 15(3):440-450. PubMed ID: 32839365
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
    Heo J; Kim YJ; Lee JW; Kim JH; Lim YS; Han KH; Jeong SH; Cho M; Yoon KT; Bae SH; Crown ED; Fredrick LM; Alami NN; Asatryan A; Kim DH; Paik SW; Lee YJ
    Gut Liver; 2021 Nov; 15(6):895-903. PubMed ID: 34053916
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Successful nasoenteric administration of glecaprevir/pibrentasvir for donor-derived hepatitis C in two young adult heart transplant recipients at a pediatric transplant center.
    Kushner LE; Puckett L; Lee J; Joerger T; Chen SF; Profita E
    Pediatr Transplant; 2022 Nov; 26(7):e14360. PubMed ID: 35854405
    [No Abstract]   [Full Text] [Related]  

  • 51. High Real-World Sustained Virologic Response Rate with Glecaprevir/Pibrentasvir at a Racially Diverse Urban Academic Medical Center.
    Martin MT; Waring N; Naveed A
    Gut Liver; 2022 May; 16(3):489-492. PubMed ID: 35145046
    [No Abstract]   [Full Text] [Related]  

  • 52. Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials.
    Brown A; Welzel TM; Conway B; Negro F; Bräu N; Grebely J; Puoti M; Aghemo A; Kleine H; Pugatch D; Mensa FJ; Chen YJ; Lei Y; Lawitz E; Asselah T
    Liver Int; 2020 Apr; 40(4):778-786. PubMed ID: 31568620
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry.
    Klinker H; Naumann U; Rössle M; Berg T; Bondin M; Lohmann K; Koenig B; Zeuzem S; Cornberg M
    Liver Int; 2021 Jul; 41(7):1518-1522. PubMed ID: 33966349
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
    Zarębska-Michaluk D; Jaroszewicz J; Pabjan P; Łapiński TW; Mazur W; Krygier R; Dybowska D; Halota W; Pawłowska M; Janczewska E; Buczyńska I; Simon K; Dobracka B; Citko J; Laurans Ł; Tudrujek-Zdunek M; Tomasiewicz K; Piekarska A; Sitko M; Białkowska-Warzecha J; Klapaczyński J; Sobala-Szczygieł B; Horban A; Berak H; Deroń Z; Lorenc B; Socha Ł; Tronina O; Flisiak R
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1944-1952. PubMed ID: 33171526
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan.
    Liu CH; Liu CJ; Hung CC; Hsieh SM; Su TH; Sun HY; Tseng TC; Chen PJ; Chen DS; Kao JH
    Liver Int; 2020 Apr; 40(4):758-768. PubMed ID: 31710759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan.
    Yu ML; Tai CM; Mo LR; Kuo HT; Huang CF; Tseng KC; Lo CC; Bair MJ; Wang SJ; Huang JF; Yeh ML; Chen CT; Tsai MC; Huang CW; Lee PL; Yang TH; Huang YH; Chong LW; Chen CL; Yang CC; Hung CH; Yang SS; Cheng PN; Hsieh TY; Hu JT; Wu WC; Cheng CY; Chen GY; Zhou GX; Tsai WL; Kao CN; Lin CL; Wang CC; Lin TY; Lin CL; Su WW; Lee TH; Chang TS; Liu CJ; Dai CY; Chen CY; Kao JH; Lin HC; Chuang WL; Peng CY
    Hepatol Int; 2024 Apr; 18(2):461-475. PubMed ID: 38246899
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients.
    Singh AD; Maitra S; Singh N; Tyagi P; Ashraf A; Kumar R; Shalimar
    Aliment Pharmacol Ther; 2020 Mar; 51(5):490-504. PubMed ID: 31943236
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.
    Lawitz E; Flisiak R; Abunimeh M; Sise ME; Park JY; Kaskas M; Bruchfeld A; Wörns MA; Aglitti A; Zamor PJ; Xue Z; Schnell G; Jalundhwala YJ; Porcalla A; Mensa FJ; Persico M
    Liver Int; 2020 May; 40(5):1032-1041. PubMed ID: 31821716
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment.
    Yap DYH; Liu KSH; Hsu YC; Wong GLH; Tsai MC; Chen CH; Hsu CS; Hui YT; Li MKK; Liu CH; Kan YM; Yu ML; Yuen MF
    Clin Mol Hepatol; 2020 Oct; 26(4):554-561. PubMed ID: 32854457
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan.
    Huang CF; Kuo HT; Chang TS; Lo CC; Hung CH; Huang CW; Chong LW; Cheng PN; Yeh ML; Peng CY; Cheng CY; Huang JF; Bair MJ; Lin CL; Yang CC; Wang SJ; Hsieh TY; Lee TH; Lee PL; Wu WC; Lin CL; Su WW; Yang SS; Wang CC; Hu JT; Mo LR; Chen CT; Huang YH; Chang CC; Huang CS; Chen GY; Kao CN; Tai CM; Liu CJ; Lee MH; Tsai PC; Dai CY; Kao JH; Lin HC; Chuang WL; Chen CY; Tseng KC; Yu ML
    Sci Rep; 2021 Dec; 11(1):23473. PubMed ID: 34873250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.